Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;22(3):563-579.
doi: 10.1007/s11154-020-09581-6.

PRRT: identikit of the perfect patient

M Albertelli  1   2 , A Dotto  1   2 , C Di Dato  3 , P Malandrino  4 , R Modica  5 , A Versari  6 , A Colao  5 , D Ferone  1   2 , A Faggiano  7   8 ; NIKE
Affiliations
Review

PRRT: identikit of the perfect patient

M Albertelli et al. Rev Endocr Metab Disord. 2021 Sep.

Abstract

Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed. The aim of this review is to define the perfect identity of the eligible patient who can mostly benefit from this therapy. Possible predictive criteria which have been analysed were: primary tumor site, grading, tumor burden, FDG PET and 68Ga-PET uptake. Primary tumor site and 68Ga-PET uptake do not play a pivotal role in predicting the response, while tumor burden, FDG PET uptake and grading seem to represent predictive/prognostic factors for response to PRRT. The heterogeneity in trial designs, patient populations, type of radionuclides, previous therapies and measurement of outcomes, inevitably limits the strength of our conclusions, therefore care must be taken in applying these results to clinical practice. In conclusion, the perfect patient, selected by 68Ga-PET uptake, will likely have a relatively limited liver tumor burden, a ki67 index <20% and will respond to PRRT irrespective to primary tumor. Nevertheless, we have mostly prognostic than predictive factors to predict the efficacy of PRRT in individual patients, while a promising tool could be the NETest. However, to date, the identikit of the perfect patient for PRRT is a puzzle without some pieces and still we cannot disregard a multidisciplinary discussion of the individual case to select the patients who will mostly benefit from PRRT.

Keywords: Neuroendocrine tumors; Peptide receptor radionuclide therapy; Predictor; Response; Therapeutic sequence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Figures

Fig. 1
Fig. 1
Study selection sequence to perform the review
See this image and copyright information in PMC

References

    1. Aalbersberg EA, Huizing DMV, Walraven I, de Wit-van der Veen BJ, Kulkarni HR, Singh A, Stokkel MPM, Baum RP. Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients. J Nucl Med. 2019;60(9):1259–1265. doi: 10.2967/jnumed.118.224386. - DOI - PubMed
    1. Adnan A, Kudachi S, Ramesh S, Prabhash K, Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nucl Med Commun. 2019;40(9):947–957. doi: 10.1097/MNM.0000000000001054. - DOI - PubMed
    1. Alexandraki, et al. Current Concepts in the Diagnosis and Management of Neuroendocrine Neoplasms of Unknown Primary Origin. Minerva Endocrinol. 2019;44(4):378–386. doi: 10.23736/S0391-1977.19.03012-8. - DOI - PubMed
    1. Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, van Echteld CJ. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine Tumours: a phase-II study. Theranostics. 2016;6(4):501–510. doi: 10.7150/thno.13702. - DOI - PMC - PubMed
    1. Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9(24):16932–16950. doi: 10.18632/oncotarget24524. - DOI - PMC - PubMed

Publication types

LinkOut - more resources